TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alaunos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.13+0.50 (+19.01%)
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.06 (+1.95%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Alaunos Therapeutics, Inc. saw revenue fall 50.0% to $3.00K over the twelve months to Jun 30, 2026. Free cash flow was -$2.97M.
Revenue
$3.00K
-50.0% vs. a year earlier
Operating income
-$4.06M
TTM Q2 2026
Free cash flow
-$2.97M
FY2025
EPS, diluted
-$1.95
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.61M
- P/E ratio
- –
- Price to sales
- 2537.07
- Price to book
- 11.67
- Dividend yield
- –
- Free cash flow yield
- -38.98%
Fundamentals
- Revenue
- $3.00K
- Net income
- -$4.01M
- EPS, diluted
- -$1.95
- Free cash flow
- -$2.97M
- Book value per share
- $0.27
- Diluted shares
- 2M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.00K-50.0% YoY
Operating income
-$4.06M
Net income
-$4.01M
EPS, diluted
-$1.95
Free cash flow
–
Reported periodTrailing twelve months